Company intelligence / Profile preview

Inhibitex

Alpharetta, Georgia, United States

Ownership: Private
Development stage: Other

Overview

INX-189, a nucleotide polymerase inhibitor, demonstrated potent antiviral activity, pan-genotypic coverage, and entered Phase 2 trials for hepatitis C virus; FV-100 (shingles pain) and Aurexis (S. aureus infections) were also in Phase 2 before acquisition[1][4][5].

Therapeutic areas: NeurologyInfectious Diseases
Modalities: Small moleculeMonoclonal antibody
Industry: Biotech

Partnerships

Pfizer (licensed MSCRAMM protein vaccine platform for staphylococcal vaccine development)

Beyond the preview

Go deeper on Inhibitex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inhibitex.

Explore the full profile